Synthesis and structure-activity relationships of carboxylated chalcones: A novel series of CysLT1 (LTD4) receptor antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 7, 1997, Pages 1075-1089

  Zwaagstra, Mariël E ^a   Timmerman, Hendrik ^a   Tamura, Masahiro ^b   Tohma, Tsutomu ^b   Wada, Yasushi ^b   Onogi, Kazuhiro ^b   Zhang, Ming Qiang ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b KOWA COMPANY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' HYDROXY 4 (2 QUINOLINYLMETHOXY) 5' (5 TETRAZOLYL)CHALCONE; CHALCONE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; DRUG ACTIVITY; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; GUINEA PIG; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRACHEA;

ANIMALS; CHALCONE; GUINEA PIGS; ILEUM; LEUKOTRIENE ANTAGONISTS; LUNG; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MUSCLE CONTRACTION; RECEPTORS, LEUKOTRIENE; STRUCTURE-ACTIVITY RELATIONSHIP; TRACHEA;

EID: 0030996616     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960628d     Document Type: Article

References (54)

1. Mayatepek, E.; Hoffmann, G. F. Leukotrienes: Biosynthesis, metabolism, and pathophysiologic significance. Pediatr. Res. 1995, 37, 1-9.
2. Chung, K. F. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy. Eur. Respir. J. 1995, 8, 1203-1213.
3. Thien, F. C. K.; Walters, E. H. Eicosanoids and asthma: an update. Prostaglandins, Leukotrienes Essent. Fatty Acids 1995, 52, 271-288.
4. Denzlinger, C.; Haberl, C.; Wilmanns, W. Cysteinyl leukotriene production in anaphylactic reactions. Int. Arch. Allergy Immunol. 1995, 108, 158-164.
5. Chanarin, N.; Johnston, S. L. Leukotrienes as a target in asthma therapy. Drugs 1994, 47, 12-24.
6. Pauwels, R. A.; Joos, G. F.; Kips, J. C. Leukotrienes as therapeutic target in asthma. Allergy 1995, 30, 615-622.
7. Hay, D. W. P.; Torphy, T. J.; Undem, B. J. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. Trends Pharmacol. Sci. 1995, 16, 304-309.
8. Henderson, J., W. R. The role of leukotrienes in inflammation. Ann. Intern. Med. 1994, 121, 684-697.
9. Larsen, J. S.; Acosta, E. P. Leukotriene-receptor antagonists and 5-Lipoxygenase inhibitors in asthma. Ann. Pharmacother. 1993, 27, 898-903.
10. Coleman, R. A.; Eglen, R. M.; Jones, R. L.; Narumiya, S.; Shimizu, T.; Smith, W. L.; Dahlen, S. E.; Drazen, J. M.; Gardiner, P. J.; Jackson, W. T.; Jones, T. R.; Krell, R. D.; Nicosia, S. Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature, Adv. Prostaglandin, Thromboxane Leukotriene Res. 1995, 23, 283-285.
11. Metters, K. M. Leukotriene receptors. J. Lipid Mediators Cell Signalling 1995, 12, 413-427.
12. Lewis, R. A.; Lee, C. W.; Levine, L.; Morgan, R. A.; Weiss, J. W.; Drazen, J. M.; Oh, H.; Hoover, D.; Corey, E. J.; Austen, K. F. Biology of the C6-sulfidopeptide leukotrienes. Adv. Prostaglandin Thromboxane Leukotriene Res. 1983, 11, 15-26.
13. Samuelsson, B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220, 568-575.
14. Sprecher, v. A.; Beck, A.; Gerspacher, M.; Bray, M. A. Peptido-leukotriene antagonists: state of the art. Chimia 1992, 46, 304-311.
15. Harris, R. R.; Carter, G. W.; Bell, R. L.; Moore, J. L.; Brooks, D. W. Clinical activity of leukotriene inhibitors. Int. J. Immunopharmacol. 1995, 17, 147-156.
16. Drazen, J. M.; Israel, E. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. Int. Arch. Allergy Immunol. 1995, 107, 319-320.
17. Drazen, J. Clinical studies with agents active on the 5-lipoxygenase pathway. Allergy 1995, 50, 22-26.
18. Gillard, J. W.; Guindon, Y. The leukotrienes: Prospects for therapy against a unique family of pathophysiological mediators. Drugs Future 1987, 12, 453-474.
19. Taylor, I. K. Cysteinyl leukotrienes in asthma: Current state of therapeutic evaluation. Thorax 1995, 50, 1005-1010.
20. 4 antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 1615-1620.
21. Borgeat, P. Leukotrienes: A major step in the understanding of immediate hypersensitivity reactions. J. Med. Chem. 1981, 24, 121-126.
22. Marshall, W. S.; Goodson, T.; Cullinan, G. J.; Swanson-Bean, D.; Haisch, K. D.; Rinkema, L. E.; Fleisch, J. H. Leukotriene receptor antagonists 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. J. Med. Chem. 1987, 30, 682-689.
23. Hay, D. W. P. SK&F 104353 2(S)-Hydroxy-3(R)-(2-carboxyethylthio)-3-[2-(8-phenyloctyl)phenyl]propanoic acid. Drugs Future 1990, 15, 240-244.
24. Gleason, J. G.; Hall, R. F.; Perchonock, C. D.; Erhard, K. F.; Frazee, J. S.; Ku, T. W.; Kondrad, K.; McCarthy, M. E.; Mong, S.; Crooke, S. T.; Chi-Rosso, G.; Wasserman, M. A.; Torphy, T. J.; Muccitelli, R. M.; Hay, D. W.; Tucker, S. S.; Vickery-Clark, L. High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propanoic acid. J. Med. Chem. 1987, 30, 959-961.
25. Perchonock, C. D.; Uzinskas, I.; McCarthy, M. E.; Erhard, K. F.; Gleason, J. G.; Wasserman, M. A.; Muccitelli, R. M.; DeVan, J. F.; Tucker, S. S.; Vickery, L. M.; Kirchner, T.; Weichman, B. M.; Mong, S.; Scott, M. O.; Chi-Rosso, G.; Wu, H. J.; Crooke, S. T.; Newton, J. F. Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: A novel class of leukotriene antagonists. J. Med. Chem. 1986, 29, 1442-1452.
26. 4) Receptor Antagonists. J. Med. Chem. 1992, 35, 1191-1200.
27. 4 Antagonist. Drugs Future 1991, 16, 432-436.
28. Abram, T. S.; Boshagen, H.; Futler, J. E.; Cuthbert, N. J.; Francis, H. P.; Gardiner, P. F.; Hartwig, W.; Kluender, H. C.; Norman, P.; Meier, H.; Rosentreter, U.; Schlemmer, K. H.; Tudhope, S. R.; Taylor, W. A. A new structural analogue antagonist of peptide leukotrienes. The discovery of BAY x7195. Bioorg. Med. Chem. Lett. 1993, 3, 1517-1522.
29. 4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides. J. Med. Chem. 1990, 33, 2621-2629.
30. Yee, Y. K.; Bernstein, P. R.; Adams, E. J.; Brown, F. J.; Cronk, L. A.; Hebbel, K. C.; Vacek, E. P.; Krell, R. D.; Snyder, D. W. A novel series of selective leukotriene antagonists: Exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. J. Med. Chem. 1990, 33, 2437-2451.
31. Brown, F. J.; Yee, Y. K.; Cronk, L. A.; Hebbel, K. C.; Krell, R. D.; Snyder, D. W. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles. J. Med. Chem. 1990, 33, 1771-1781.
32. Jacobs, R. T.; Brown, F. J.; Cronk, L. A.; Aharony, D.; Buckner, C. K.; Kusner, E. J.; Kirkland, K. M.; Neilson, K. L. Substituted 3-(Phenylmethyl)-1H-indole-5-carboxamides and 1-(Phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes. J. Med. Chem. 1993, 36, 394-409.
33. Brown, F. J. In The Search for Antiinflammatory Drugs. Case Histories from Concept to Clinic; Merluzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; pp 161-189.
34. Toda, M.; Nakai, H.; Kosuge, S.; Konno, M.; Arai, Y.; Miyamoto, T.; Obata, T.; Katsube, N.; Kawasaki, A. A potent antagonist of the slow-reacting substance of anaphylaxis. Adv. Prostaglandin Thromboxane Leukotriene Res. 1985, 15, 307-308.
35. 4. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1988, 31, 84-91.
36. Yamada, N.; Yamada, K.; Takahashi, K.; Nakao, E.; Kadowaki, S.; Umezu, K. Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-Diethyl-3′-[2-[2-(4-isopropyl)thiazolyl]ethenyl]siccinanilic acid. Arzneim.-Forsch./Drug Res. 1994, 44, 749-753.
37. 4. J. Pharmacol. Exp. Ther. 1991, 259, 751-758.
38. 4 receptor binding affinity. J. Med. Chem. 1991, 34, 1704-1707.
39. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5, 283-288.
40. 4. J. Med. Chem. 1995, 38, 2472-2477.
41. 4 antagonists. Eur. J. Med. Chem. 1996, 31, 861-874.
42. Pfister, J. R. Neue 1,4-Benzopyron-6-carbonsauren und Verfahren zu ihrer Herstellung und Verwendung. Ger. Offen. C 07 D 311.30, April 17, 1975.
43. Wurm, G.; Geres, U. Potentiell antianaphylaktische 5′-und 6′-carboxyflavonderivate. Arch. Pharm. 1977, 310, 119-128.
44. Wurm, G.; Geres, U. Potentiell antianaphylaktische 2′-und 6-carboxy-flavonolderivate. Arch. Pharm. 1978, 311, 177-183.
45. Wurm, G.; Geres, U. Struktur-Wirkungs-Untersuchung an antianaphylaktisch aktiven Flavoncarbonsaure-Derivaten. Arzneim.-Forxch./Drug Res. 1979, 29 (1), 15-18.
46. Doria, G.; Romeo, C.; Giraldi, P.; Lauria, F.; Sberze, P.; Tibolla, M.; Corno, M. L.; Cadelli, G.; Montoro, C. Antiallergic agents. I. Substituted 4-oxo-4H-1-benzopyran-6-carboxylic acids. Eur. J. Med. Chem.-Chim. Ther. 1978, 13, 33-39.
47. Dhar, D. N. The Chemistry of Chalcones and Related Compounds; John Wiley & Sons, Inc.: New York, 1981.
48. De Meyer, N.; Haemers, A.; Mishra, L.; Pandey, H. K.; Pieters, L. A. C.; Vanden Berghe, D. A.; Vlietinck, A. J. 4′-Hydroxy-3-methoxyflavones with Potent Antipicornavirus Activity. J. Med. Chem. 1991, 34, 736-746.
49. Sekizaki, H. Bull. Chem. Soc. Jpn. 1988, 61, 1407-1409.
50. 4 antagonist L-660,711. J. Org. Chem. 1989, 54, 3718-3721.
51. 4/PAF receptor antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 1377-1382.
52. 4 antagonists of novel structure. J. Med. Chem. 1990, 33, 240-245.
53. 4-receptors. Eur. J. Med. Chem., in press.
54. Appleton, R. A.; Bantick, J. R.; Chamberlain, T. R.; Hardern, D. N.; Lee, T. B.; Pratt, A. D. Antagonists of slow reacting substance of anaphylaxis. Synthesis of a series of chromone-2-caraboxylic acids. J. Med. Chem. 1977, 20, 371-379.